|
Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials. |
|
|
Honoraria - Celgene; Roche |
Consulting or Advisory Role - Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer Schering Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - AstraZeneca/MedImmune (Inst) |
Other Relationship - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Tesaro (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Clovis Oncology; Pfizer; Roche; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; AstraZeneca; Celgene |
Consulting or Advisory Role - Amgen |
|
|
No Relationships to Disclose |
|
Rosalind Margaret Glasspool |
Consulting or Advisory Role - Clovis Oncology; Clovis Oncology; Roche; Tesaro |
Research Funding - Boehringer Ingelheim (Inst); Ignyta (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Roche; TESARO |